NewsRoom Articles - Page 20 of 53

WednesdayFeb 14, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial

Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to have broad therapeutic utility Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the submission of its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”)…

TuesdayFeb 13, 2024 9:45 am

GEMXX Corp. (GEMZ) Anticipates Significant Growth over the Next 24 Months on ‘Tremendous Potential’ in Ammolite and Gold Markets

GEMXX expects the growing demand for Ammolite, coupled with the positive outlook for gold prices, to support significant growth over the next 24 months Last year, GEMXX moved to complement its Ammolite operations with the purchase of gold assets in Canada The price of gold has held steady above US$2,000 per ounce, coming off a record-breaking 2023 when it rallied to a record-high year-end close The future looks promising for gold because it is projected to reach new highs in the coming months, according to GEMXX The price of an ounce of gold rallied to a record high year-end close…

MondayFeb 12, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter

Lexaria, a global innovator in drug delivery platforms, just announced ambitious plans for the 2024 calendar year The letter confirms that the 2024 plans have been made possible by significant strides that were made by the company in 2023 Lexaria looks to build on the momentum gained from the previous year, ultimately asserting market dominance and making 2024 its best year yet Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its ambitious plans for the 2024 calendar year. In his annual letter, Chris Bunka, Lexaria’s CEO, noted that this would mark the year that will…

MondayFeb 05, 2024 11:15 am

Diamond Lake Minerals Inc. (DLMI) Emphasizes Regulatory Safety Framework While Building Bridge to Digital Asset Investments

Traditional investors often hold onto real world assets (“RWAs”) with the expectation that their risk factors are known and manageable, while avoiding digital assets because of potential volatility and uncertainty about what actually underpins their risk factors Utah-based Diamond Lake Minerals Inc. is building a vertically integrated portfolio of noteworthy subsidiaries that will be infused with security token offerings as digital assets bridged to RWAs DLMI is working in conjunction with the U.S. Securities and Exchange Commission, SEC-registered digital asset exchange INX, to provide heightened security to digital offerings DLMI’s portfolio will include industry-agnostic holdings that span real estate, wireless…

ThursdayFeb 01, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap

Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the improved delivery of the GLP-1 drug semaglutide, available commercially in the branded product Rybelsus(R) The company’s chronic dosing animal study and its second human pilot study will commence in Spring and run for 12 weeks. The third human pilot study will start in May or June These studies will evaluate DehydraTECH for the improved…

WednesdayJan 31, 2024 12:00 pm

Diamond Lake Minerals Inc. (DLMI) Serves As ‘Missing Link’ to Help Traditional Investors Enter Evolving Digital Asset Sector

The U.S. Securities and Exchange Commission recently won a judgment that furthers its efforts to bring crypto-based transactions under its purview, seen as enhancing the sense of security needed for larger public acceptance of the digital sector Many investors have taken an interest in the heady accomplishments of the digital asset sector but have been reluctant to get involved due to uncertainties or a simple wariness of having to become tech savvy Utah-based Diamond Lake Minerals Inc. is positioning itself as a bridge-builder that helps traditional investors step effortlessly into the digital asset sector with expectations of government-regulated stability DLMI’s…

WednesdayJan 31, 2024 10:30 am

GEMXX Corp. (GEMZ) Sequire Presentation Demonstrates Major Competitive Advantage with Control of the Mining Value Chain

GEMXX recently presented at the Sequire Investor Summit 2024, showing how their dgreater control of the mining value chain represents a significant competitive advantage The company shared its knowledge and expertise in all stages of its production, including gold mining, gemstone (Ammolite) production, jewelry manufacturing, and global distribution GEMXX continues to control all stages of its production, which enables it to manage its mining value chain and support its mine-to-market strategy According to a McKinsey report, mining companies that manage their value chain well can establish a significant source of competitive advantage and value creation GEMXX (OTC: GEMZ), a company…

MondayJan 29, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Hit High Ground in Q2 and Q3 2024 with Animal and Human GLP-1 Study Programs

Lexaria, a global innovator in drug delivery platforms, has announced its GLP-1 research plans for the 2024 calendar year The company will kick off its chronic dosing animal study in March/April, followed by the human pilot study #2, kicking off at around the same time The third human pilot study will start in May/June followed by a chronic dosing human study that will involve 70-90 pre-diabetic and type-2 diabetic human patients These studies will evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies Lexaria Bioscience (NASDAQ: LEXX), a global innovator…

MondayJan 29, 2024 10:30 am

Diamond Lake Minerals Inc. (DLMI) Builds Digital Token Bridge to Traditional Stocks, Bonds Market

The hoopla surrounding crypto offerings’ highs and lows has attracted scores of new investors in a sort of modern-day gold rush, but the unfamiliarity of the sector to many traditional investors has been off-putting Utah-based Diamond Lake Minerals Inc. is redefining itself to attract digital asset-wary investors, by imbuing real world asset subsidiaries with security token offerings registered with the U.S. Securities and Exchange Commission (“SEC”) The company’s board members are experienced professionals, and its CEO has been ranked among the world’s Top 10 CEOs for three consecutive years recently by Adria Management, LLC in its World CEO Rankings Awards…

FridayJan 26, 2024 9:45 am

Revolutionary Vision Marine Technologies Inc. (NASDAQ: VMAR) Tech Powers Boat-of-the-Year Winner

Powered by VMAR’s E-Motion engine, the Four Winns H2e was named winner in “Boating” magazine’s annual Boat of the Year competition The award announcement called out the torque provided by the Vision Marine Technologies 180e electric outboard Vision Marine is dedicated to pioneering the clean-energy transition on the water “Boating” magazine announced its Boat of the Year category winners for 2023, and the Four Winns H2e came out on top in the Runabout category (https://ibn.fm/5O7Ls). The Four Winns bowrider is powered by Vision Marine Technologies’ (NASDAQ: VMAR) E-Motion, an 180 HP electric outboard engine that is the most powerful marine…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000